The number of new graduates hired for sales rep roles increased in FY2025 after declining for five consecutive years, a…
HOME > COMMENTARY
COMMENTARY
-
New Grad Hires for Sales Reps Up after 5 Years of Decrease: FY2025 Survey
May 8, 2025
-
How Will Japan Deal with Expected Cost Spike with Japan-Made Antibiotic APIs?
April 1, 2025
-
Fair or Unfair? PMP Return Applied for First Time in Off-Year Revision
March 24, 2025
-
Evolving GLP-1 Drugs: Could Double and Triple Agonists Achieve Blockbuster Status?
March 4, 2025
-
New Govt Fund for Innovative Drugs: Twists, Turns, and Hope
February 10, 2025
-
Companies Welcome Generic Drug Fund, but Fret Pricing and Regulations
February 5, 2025
-
Japan’s Redefinition of “High-Priority” Vaccines Likely to Speed Up Discussions on NIP Access
January 27, 2025
-
Japan Expects to Approve/List 43 Novel Drugs in 2025 Including Ultra-Expensive Gene Therapies
January 9, 2025
-
Where Do Japan Drug Makers Stand? A Comparison with Other Industries and Mega Pharma Peers
December 24, 2024
-
Battle over Off-Year Price Revision Now Heading for Political Settlement
December 13, 2024
-
Drug Price Gap Hits Record Low, Did Distribution Guidelines Play Any Role?
December 10, 2024
-
Japan Needs Transparent Debates amid Growing “No” to Off-Year Revisions
December 2, 2024
-
MOF Stands Pat with Off-Year Revisions despite Change in Politics, Does this Hint at Govt’s Reform Directions?
November 27, 2024
-
With 1/4 of Pharma Backers Losing Seats, It’s Time for Industry to Revamp Lobbying Activities
November 11, 2024
-
Survey Hints LLP New Coverage Rule Could Push Generic Switches for Cancer Drugs, Pediatric Meds
October 8, 2024
-
LLP Info Might Become Inaccessible If New Coverage Rule Speeds Up Exit
September 10, 2024
-
Japan’s Drug-Loss Landscape Is Transforming Driven by Private Sector
August 21, 2024
-
How Will Simplified Delisting, Elective Care Affect G1 Withdrawal Scheme?
August 7, 2024
-
Analysis: All Eyes Riveted on FY2024 Drug Price Survey for Off-Year Revision
August 6, 2024
-
Lively Debate on Generic Industry Revamp Underway, All Eyes on Consortium Model
July 12, 2024
ページ
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…